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Abstract: Recent studies suggested that simian virus 40 (SV40) may cause malignant mesothelioma,
although the pathogenic mechanism is unclear. We found that in SV40-positive malignant mesothelioma
cells, the hepatocyte growth factor (HGF) receptor (Met) was activated. In human mesothelial cells
(HMC) transfected with full-length SV40 DNA (SV40-HMC), Met receptor activation was associated with
S-phase entry, acquisition of a fibroblastoid morphology, and the assembly of viral particles. Coculture
experiments revealed the ability of SV40-HMC to infect permissive monkey cells (CV-1), HMC, and
murine BNL CL cells. Cocultured human and murine SV40-positive cells expressed HGF, showed Met
tyrosine phosphorylation and S-phase entry, and acquired a spindle-shaped morphology (spBNL), whereas
CV-1 cells were lysed. Cocultured HMC inherited from SV40-HMC the infectivity, as they induced lysis
in cocultured CV-1 cells. Treatment with suramin or HGF-blocking antibodies inhibited Met tyrosine
phosphorylation in all large T antigen (Tag)-positive cells and reverted the spindle-shaped morphology
of spBNL. This finding indicated that Met activation and subsequent biological effects were mediated
by an autocrine HGF circuit. This, in turn, was causally related to Tag expression, being induced by
transfection with the SV40 early region alone. Our findings suggest that when SV40 infects HMC it
causes Met activation via an autocrine loop. Furthermore, SV40 replicates in HMC and infects the
adjacent HMC, inducing an HGF-dependent Met activation and cell-cycle progression into S phase. This
may explain how a limited number of SV40-positive cells may be sufficient to direct noninfected HMC
toward malignant transformation.
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Recent studies suggested that simian virus 40 (SV40) may cause
malignant mesothelioma, although the pathogenic mechanism is
unclear. We found that in SV40-positive malignant mesothelioma
cells, the hepatocyte growth factor (HGF) receptor (Met) was
activated. In human mesothelial cells (HMC) transfected with
full-length SV40 DNA (SV40-HMC), Met receptor activation was
associated with S-phase entry, acquisition of a fibroblastoid mor-
phology, and the assembly of viral particles. Coculture experiments
revealed the ability of SV40-HMC to infect permissive monkey cells
(CV-1), HMC, and murine BNL CL cells. Cocultured human and
murine SV40-positive cells expressed HGF, showed Met tyrosine
phosphorylation and S-phase entry, and acquired a spindle-shaped
morphology (spBNL), whereas CV-1 cells were lysed. Cocultured
HMC inherited from SV40-HMC the infectivity, as they induced lysis
in cocultured CV-1 cells. Treatment with suramin or HGF-blocking
antibodies inhibited Met tyrosine phosphorylation in all large T
antigen (Tag)-positive cells and reverted the spindle-shaped mor-
phology of spBNL. This finding indicated that Met activation and
subsequent biological effects were mediated by an autocrine HGF
circuit. This, in turn, was causally related to Tag expression, being
induced by transfection with the SV40 early region alone. Our find-
ings suggest that when SV40 infects HMC it causes Met activation via
an autocrine loop. Furthermore, SV40 replicates in HMC and infects
the adjacent HMC, inducing an HGF-dependent Met activation and
cell-cycle progression into S phase. This may explain how a limited
number of SV40-positive cells may be sufficient to direct noninfected
HMC toward malignant transformation.
Malignant mesothelioma (MM) is an aggressive and invasivecancer with high mortality because it is resistant to current
therapies (1, 2). It has been estimated that one-quarter million
people will die of MM in Europe in the next three decades (3).
Prolonged exposure to asbestos is a well-known risk factor for
MM, and the cooperation of other carcinogens with asbestos in
the onset of this neoplasm seems possible (1, 2).
The simian virus 40 (SV40) oncoprotein large T antigen (Tag)
plays a crucial role in the transformation of human cells (4) and
causes cell-cycle derangement of human mesothelial cells (HMC)
(5). The effects of Tag are caused by its ability to bind the tumor
suppressor gene products p53 and retinoblastoma family (Rb)
proteins (6, 7). The direct involvement of SV40 Tag expression in
the growth of malignant mesothelioma cells has been described (8),
and SV40 is associated with a shorter survival of MM patients (9).
A synergistic action between SV40 and asbestos fibers has been
suggested (10), and HMC have been shown to be highly sensitive to
SV40-mediated transformation (11).
In an animal model, the high growth rate and in vivo tumorige-
nicity of the neoplastic cells from SV40-dependent MM were shown
to be associated to insulin-like growth factor-1 release (12).
Several studies investigated the potential involvement of other
growth factors, like platelet-derived growth factor A and B (13),
insulin-like growth factor-1 (14), transforming growth factor b,
fibroblast growth factor-2 (15), and hepatocyte growth factor
(HGF) (16–19) in the onset of MM. High levels of HGF, in
particular, were detected in pleural effusion from patients with
MM (20).
HGF is a heterodimeric, glycosylated protein made of a heavy
a chain and a light b chain, linked by an interchain disulfide
bond. The active form is generated by cleavage of the biologically
inactive monomeric precursor. The high affinity receptor of
HGF is the MET protooncogene product (p190Met), a trans-
membrane receptor tyrosine kinase, made of a 145-kDa b
subunit and a 50-kDa a subunit, synthesized as a single chain
precursor of 170 kDa and linked by disulfide bridges. The a chain
and the N-terminal portion of the b chain are exposed on the cell
surface, whereas the C-terminal portion of the b chain is located
in the cytoplasm and contains the tyrosine kinase domain and
phosphorylation sites involved in the regulation of enzyme
activity and signal transduction. HGF-induced Met oligomer-
ization and activation leads to cell growth, motility, and mor-
phogenesis in cells of different origin (21). It is worth noting that
a fragile site for SV40 integration has been reported on chro-
mosome 7 (22), where human HGF and its receptor, the Met
tyrosine kinase, colocalize (23, 24).
In the present work, we investigated whether SV40 induced
HGF expression in HMC and in turn could play a role in MM
tumorigenesis.
Materials and Methods
Cell Cultures. MM cells were derived from pleural effusion of MM
patients, whereas HMC cell cultures were obtained from pleural
effusion of patients with heart failure. The other cell lines were
purchased from the American Type Culture Collection. MM and
HMC cell lines were characterized as described (25, 26). Cells
were cultured in RPMI 1640, DMEM, and Ham’s F-10 medium
supplemented with 10–15% FBS (GIBCO) and maintained at
37°C in a 5% CO2-humidified atmosphere. Stable transfectants
were obtained by transfection of pSV3neo plasmid expressing
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Tag and SV40 full-length DNA by using the polycation com-
pound Superfect (Qiagen, Chatsworth, CA). The following
selection was performed in growth medium supplemented with
0.8 mgyml G418-sulfate (GIBCO). Stable cell cultures were
examined by immunoblotting, by using a mAb to Tag (Ab-1,
Oncogene Science). Cocultures were performed in Transwell
chambers (Costar). SV40-HMC cells were seeded on the upper
side of a porous polycarbonate membrane (8.0-mm pore size),
whereas target cells were seeded in the lower chamber.
Biochemical Assays. Immunoprecipitation and immunoblotting
were performed as described (27). Proteins from cell lysates
were immunoprecipitated with anti-Tag (Ab-1) and anti-Met
(C-28, Santa Cruz Biotechnology) antibodies. The immunocom-
plexes were washed, and proteins from immunoprecipitates were
solubilized in Laemmli buffer and run in reducing conditions.
The proteins were separated on SDSyPAGE and transferred to
nitrocellulose filters (Hybond, Amersham Pharmacia). Filters
were probed with the appropriate antibodies and detected by the
enhanced chemiluminescence system (ECL, Amersham Phar-
macia). Tyrosine phosphorylation was evaluated by immuno-
blotting as described above on immunoprecipitates, by using
phosphotyrosine monoclonal antibody (4G10, Upstate Biotech-
nology, Lake Placid, NY).
PCR and Reverse Transcriptase (RT)-PCR. Genomic DNA (250 ng)
were PCR-amplified (1 min at 95°C, 30 s at 56°C, 16 s at 72°C for
35 cycles). The oligomers used were SV5, 59-TAGGTGCCAAC-
CTATGGAACAGA-39 and SV6, 59-GAAAGTCTTTAGGG-
TCTTCTACC-39.
Total RNA (400 ng), extracted with the guanidinium thiocy-
anate system (Rneasy Kit, Qiagen), was used for reverse tran-
scription (Accept RT-PCR kit, Promega). The oligomers used
were HGF forward, 59-GGGGAGAGTTATCGAGGTCTC-39
and HGF reverse, 59-CAAACTAACCATCCATCCTATG-39.
Southern hybridization of DNA or cDNA were performed as
described (28). DNAycDNA was transferred on nylon mem-
branes (Hybond-N1, Amersham Pharmacia), and filters were
hybridized with HGF or SV40 probes, radiolabeled with
[a-32P]dCTP (specific activity 3,000 Ciymmol, Amersham Phar-
macia) by using the Random-Primed kit (Roche Molecular
Biochemicals).
Cell-Cycle Analysis. Ethanol-fixed cells were washed twice in PBS
and stained for 30 min at room temperature with 10 mgyml
propidium iodide in 0.1 M PBS, pH 7.2, containing 100 unitsyml
RNase. Cell-cycle analysis was carried out by using a DAKOy
Partec PAS III flow cytometer (Glostrup, Denmark) under the
following conditions: Argon ion laser excitation power 50 mW at
488-nm, 610-nm long pass filter for the red fluorescence (pro-
pidium iodide) detector.
Scatter Assay. Madin–Darby canine kidney (MDCK) cells (1.5 3
103) were seeded on 96-well dishes in DMEM supplemented with
5% FBS. After 12 h, cells were exposed to concentrated condi-
tioned medium or control medium. Recombinant HGF was
released by transiently transfected N-2A cells in the medium,
harvested, and stored at 4°C. Serum-free culture media of
mesothelioma cell lines and BNL CL cells were harvested after
4 days’ culture, cleared by centrifugation, and concentrated 203.
HGF was activated in 5% FBS at 37°C for 1 h; these media were
sterilized and added to MDCK cells.
Suramin Treatment and Blocking Antibodies. Subconfluent cells
were exposed to suramin (350 mgyml) for 24 h, then washed three
times with sterile PBS and trypsinized. After washing in PBS, the
pellet was resuspended in culture medium containing 10 mgyml
blocking antibodies anti-HGF (mAb 294, R & D Systems). Cells
were maintained in suspension for 1 h at 22°C before being
plated again.
Electron Microscopy. Cells were trypsinized and suspended in their
medium, centrifuged, and suspended in sodium cacodilate-
glutaraldehyde solution. Ultrastructural pictures were taken
with a Hitachi 800 electron microscope.
Results
Met Activation and Tag Expression in MM Cell Lines. To test whether
Tag expression was associated with Met tyrosine kinase activity,
we examined nine cell lines established from pleural effusions of
nine individuals with MM.
Expression and tyrosine phosphorylation of Met were inves-
tigated by immunoprecipitation followed by immunoblotting,
using Met and phosphotyrosine-specific antibodies. Met was
found expressed in seven of nine MM cell lines (Fig. 1A), and in
two of them (MMP and MMCa) it was phosphorylated on
tyrosine (Fig. 1B).
PCR and Southern hybridization analysis of genomic DNA
performed on these MM cells using nucleotides 4402–4574 of
SV40 genome (4) revealed the presence of the SV40 early region
sequences only in those cell lines that expressed Met in the
activated (phosphorylated) form (MMP and MMCa). These
viral sequences were transcriptionally active because we dem-
onstrated Tag expression by RT-PCR in the same cells. Tag was
not detected in the other seven cell lines, suggesting a specific
association with phosphorylated Met (Fig. 1D).
Fig. 1. Expression of Met and Tag by MM cell lines. (A) Equal amounts of
solubilized proteins were immunoprecipitated with Met antibodies, sepa-
rated by SDSyPAGE, transferred to nitrocellulose filter, and probed with the
same antibodies. Asterisks on the right indicate the pr170MET precursor (**)
and the mature b-chain (p145MET, *). (B) The same filter was reprobed with
antiphosphotyrosine antibodies. (C) Tag sequence (*, nucleotides 4402–4574)
was amplified by PCR from genomic DNA. (D) RT-PCR was performed on MM
cells and COS-7 cells to amplify a fragment of Tag cDNA (172 bp), indicated by
the asterisk on the right. (E) Electron microscopy of MMP cells. (Original
magnification: 340,000.)
















































The presence of SV40 was confirmed by the detection of viral
particles by electron microscopy in MMP cells (Fig. 1E).
Met Activation and S-Phase Entry Are Induced by Tag Expression in
Mesothelial Cells. HMC expressing the Met receptor were trans-
fected either with Tag-encoding cDNA (Tag-HMC) or SV40
DNA (SV40-HMC). Immunoprecipitation and immunoblotting
performed on Tag-positive clones showed that both types of
transfectants displayed Met tyrosine phosphorylation in associ-
ation with the expression of SV40 Tag (Fig. 2 A–D). Interest-
ingly, also the expression of the endogenous Met receptor was
increased in Tag-expressing HMC (Fig. 2C).
To investigate the effects of Tag-induced Met activation on the
cell cycle, mesothelial cells were also analyzed by cytofluorim-
etry. Baseline cell-cycle analysis of HMC showed a very slow
pattern of growth. Cell-cycle phases were not clearly distinguish-
able, with few proliferating cells. After SV40 transfection, a clear
cell-cycle distribution was detected, with a large percentage of
cells (35%) in the S phase (Fig. 2E). Significant entry in the S
phase was obtained also with Tag-HMC (data not shown).
SV40-HMC Are Virus Reservoirs and Cause Morphological Changes and
Cell-Cycle Progression in Target Cells. To verify whether SV40
transfection could influence neighboring cells, we performed
coculture experiments by using the Transwell system. Transwell
allows cell growth in two chambers, separated by a porous set
that can be crossed by solutes and particles of definite size,
including SV40. As targets, we used CV-1 monkey kidney
epithelial cells, murine BNL CL, and HMC.
CV-1 cells are permissive to SV40 infection. CV-1 cells were
cocultured with SV40-HMC transfectants and monitored every
24 h. After 4 days, early symptoms of cell crisis (vacuolization,
loss of adherence, and death) in CV-1 cocultured with SV40-
HMC were detected. After 5 additional days, all cells died (Fig.
3B), and viral particles were visible in the cell debris fraction
(Fig. 3C). The molecular identity of the virus was assessed by
PCR amplification of SV40 DNA early region (nucleotides
4402–4574), both in infected CV-1 cells and their conditioned
medium (Fig. 4A).
Moreover, immunoblotting confirmed Tag expression in these
cells at early stages of infection, i.e., 4 days after the onset of the
coculture experiment (Fig. 3B).
Murine BNL CL cells are nonpermissive, as they can be
infected but do not allow SV40 replication. In addition, these
cells express the Met receptor, which can be activated in an
HGF-dependent manner, leading to growth, scatter, and migra-
tion (29). Coculture with SV40-HMC induced a clear-cut mor-
phological change in epithelial BNL CL target cells (BNL
CLySV40), which lost their original morphology and became
elongated and spindle-shaped; we identified these cells as spBNL
to distinguish them from the parental cells (Fig. 3E). The
morphological changes were caused by viral replication in SV40-
HMC in which viral particles were detected (Fig. 4E) because
Tag-HMC (with Tag expression but no viral replication) did not
exert any morphological effects on BNL CL cells (data non
shown). In spBNL, PCR amplification of genomic DNA revealed
the presence of SV40 DNA sequences (Fig. 4A), and immuno-
Fig. 2. Transfection of HMC cells with Tag and SV40 DNA. (A) Tag sequence
(*) was amplified by PCR from genomic DNA of COS-7 (control), HMC, Tag-
HMC, and SV40-HMC cells. (B) Tag protein (*) was detected in cell lysates
immunoprecipitated and probed with Tag antibodies. (C) Immunoblotting
was performed on Met immunoprecipitates with Met antibodies. GTL-16 cell
line was used as a control of Met expression and phosphorylation. Asterisks on
the right of the blot indicate the positions of the pr170MET precursor (**) and
p145MET (*). (D) The same filter was reprobed with antiphosphotyrosine
antibodies. (E) Citofluorimeter analysis of HMC cells before (Left) and after
(Right) transfection with SV40 DNA.
Fig. 3. Morphology after cocultures with SV40-HMC. The morphology of
target cells CV-1 (A), BNL CL (D), and HMC (G) changed after coculture with
SV40-HMC cells (B, E, and H, respectively). SV40 particles were observed by
electron microscopy (C and I). (F) No virions were detected in nonpermissive
BNL CL cells. CV-1 cells underwent vacuolization and massive lysis, accompa-
nied by Tag expression. Tag protein (*) was detected in cell lysates immuno-
precipitated and probed with Tag antibodies. (Original magnifications: A, B,
D, E, G, and H, 3320; C, 350,000; F and I, 340,000.)








































blotting demonstrated expression of Tag protein (Fig. 4D). As
expected, no viral particles were detected in these cells (Fig. 3F)
because murine cells are not permissive to SV40 replication.
HMC are semipermissive cells because they can be infected
and allow replication at low titer (11). After 20 days of coculture
with SV40-HMC transfectants, viral particles were detected in
HMC target cells (HMCySV40, Fig. 3I), and these cells under-
went morphological changes (Fig. 3H). This cells also acquired
the ability to infect nearby cells as confirmed by the massive lysis
of CV-1 cells, induced by coculturing together targeted HMCy
SV40 and CV-1 cells (data not shown).
Cell-cycle analysis demonstrated that cocultured HMCySV40
and spBNL cells displayed a higher rate of S-phase entry
compared with cells not exposed to SV40-HMC culture medium
(Fig. 5).
SV40-Mediated Tag Expression Induces an HGF Autocrine Circuit.
Immunoprecipitation and immunoblotting showed that the Met
receptor became spontaneously tyrosine-phosphorylated in
HMC and in spBNL cocultured with SV40-HMC because of
SV40 infection (Fig. 3 B and C).
The conditioned medium from nonpermissive spBNL dis-
played scatter activity on MDCK cells, revealing the acquired
ability to express and release HGF (Fig. 6E). The scatter activity
was also detected in conditioned medium of human MMP and
MMCa cells (Fig. 6C) but not in MMM (Fig. 6D). This finding
suggests that in MM cells the Met activation can be explained by
an HGF-autocrine loop. To test this hypothesis, RT-PCR using
oligonucleotides specific for HGF sequences was performed on
MM cells, as well as on spBNL and HMCySV40. The results
revealed the presence of HGF transcripts in these cells, suggest-
ing that an autocrine circuit underlies Met activation in MM cells
as well as in cocultured models (Fig. 6F).
To confirm the existence of the HGF-mediated autocrine
Fig. 4. Coculture experiments. (A) Tag sequence (*) was amplified by PCR
from genomic DNA of CV-1, BNL CL, and HMC. PCR without DNA (lane 1) and
with COS-7 DNA (lane 2) were also performed as controls. Shown is the
product of PCR amplification performed on lysates from cells cocultured with
Tag-HMC (a) and SV40-HMC (b). The same PCR amplification was also per-
formed on the SV40-HMC coculture medium (c). (B) Solubilized proteins from
cell lysates were immunoprecipitated with Met antibodies and probed with
the same Met antibodies and (C) with the antiphosphotyrosine antibodies.
Asterisks on the right indicate the positions of the pr170MET precursor (**) and
p145MET (*). (D) Tag protein (*) was detected in cell lysates immunoprecipi-
tated and probed with Tag antibodies. (E) Electron microscopy of SV40-HMC
cells. (Original magnification: 360,000.)
Fig. 5. Cell cycle of HMC and BNL CL cocultured cells. Cytofluorimeter
analysis before (A and C) and after (B and D) coculture with SV40-HMC cells.
Fig. 6. MetyHGF autocrine loop. Scatter assay was performed on the MDCK
cell line. Shown are untreated MDCK cells (A) and MDCK stimulated with
recombinant HGF (B), with MMP-conditioned medium (C), with MMM-
conditioned medium (D), and with spBNL-conditioned medium (E). (Original
magnification: 3320.) (F) RT-PCR and Southern hybridization specific for HGF
(nucleotides 646-1533). Cell lines expressing activated Met (MMP, lane 4;
MMCa, lane 5; Tag-HMC, lane 6; SV40-HMC, lane 7; HMCySV40, lane 9; and
spBNL, lane 11) display HGF expression (*), whereas HGF cDNA was not
amplified in MMM (lane 3), HMCyTag (lane 8), and BNL CL (lane 10) cells as well
as in RT-PCR control without RNA (lane 1). MRC5 cell line (lane 2) was used as
a control of HGF expression.
















































loop, we performed inhibition experiments using HGF-blocking
antibodies. Cells in suspension were incubated for 1 h with
commercial antibodies certified for blocking the HGF-receptor
interaction. Then, cells were seeded and grown in the continuous
presence of the antibodies. After 48 h, the reversion of the
dissociated (scattered) phenotype was already evident, and cell
islets remained detectable during the next 3 days (Fig. 7A). The
interference on the autocrine loop was confirmed by immuno-
blotting with phosphotyrosine antibodies that revealed inhibi-
tion of Met tyrosine phosphorylation only in anti-HGF-treated
cells and not in cells treated with control antibodies (Fig. 7B).
Similar results were obtained by cell treatment with suramin, a
well-known chemical agent that minimizes protein–protein in-
teractions on the cell surface (data not shown).
The SV40 Tag-Induced HGF Autocrine Circuit Is Rb-Dependent. It has
been reported that in MDCK cells, Tag may induce HGF
expression in an Rb-dependent manner (30). As an attempt to
understand the mechanism for HGF induction in SV40 Tag-
expressing mesothelial cells, we used two defective SV40 Tag
mutants, kindly provided by V. De Simone (University of
Naples, Italy). One mutant, TagM, carries the E1073K amino
acid substitution that impairs the binding of Tag to the Rb
protein. The other mutant, Tag2M, has an additional D4023E
substitution that blocks also the binding to p53. HMC were
transfected either with TagM (TagM-HMC) or with Tag2M
(Tag2M-HMC) cDNAs and compared with HMC transfected
with wild-type Tag cDNA (Tag-HMC). Immunoprecipitation
and immunoblotting performed on Tag and mutant-positive
clones showed that all cells expressed the Met receptor (Fig. 8A),
even though at relatively higher levels, as well as Tag proteins
(Fig. 8C), but in cells expressing both types of Tag mutants, Met
was not tyrosine phosphorylated (Fig. 8B). Consequently, RT-
PCR analysis revealed the absence of HGF transcripts in Tag
mutant-expressing cells (Fig. 8D), demonstrating that binding of
Tag to Rb is an essential requisite for the onset of the HGF
autocrine circuit, underlying Met activation in MM cells as well
as in cocultured cells.
Discussion
Our results show that in MM-derived cell lines expressing the
SV40 Tag protein, the Met receptor is constitutively phosphor-
ylated. Activation of the Met receptor occurs in these cells
through a Tag-induced HGF-dependent autocrine circuit. This is
demonstrated by the presence of scatter activity in conditioned
medium of the Tag-positive MM cells, expression of the HGF
transcript, and inhibition of Met phosphorylation in these same
cells, upon treatment with HGF-blocking antibodies or suramin.
Transfection of SV40 full-length DNA or Tag-encoding se-
quences in HMC cells caused alterations of growth rate and
morphology. The consequent establishment of an HGF auto-
crine circuit, mimicking that occurring in SV40-positive MM
cells, may reinforce or add to the known effects of Tag inter-
action with Rb or p53 oncosuppressor gene products (6, 7).
Coculture experiments between SV40-transfected HMC and
target cells of different origin confirmed that SV40 does repli-
cate in HMC, in agreement with recent similar data (11). The
virus propagates to adjacent cells, which in turn undergo the
same modifications of the original reservoir SV40-HMC cells,
i.e., Met tyrosine phosphorylation, HGF release, cell-cycle pro-
gression, and mesenchymal conversion. Coculture of SV40-
HMC with HMC that are permissive cells determines a new viral
replication cycle in these latter cells, allowing a chain reaction
leading to a dissemination of the same effects in the whole cell
population.
We demonstrate here that in HMC, HGF synthesis and release
strictly depends on Tag protein expression. Accordingly, the
mere transfection of the Tag-encoding sequence (SV40 early
region) is sufficient to cause HGF synthesis and release. Indeed,
the HGF release by Tag-HMC can activate Met on the neigh-
boring cells. A similar mechanism has been reported in myeloma
caused by Kaposi’s sarcoma-associated herpes virus infection,
where an IL-6 paracrine release by virus-infected cells is respon-
sible for malignant transformation of plasma cells (31).
Induction of an HGF autocrine loop has been obtained by
SV40 Tag transfection in MDCK cells, where the involvement of
Fig. 7. MetyHGF autocrine loop. (A) spBNL cells were photographed before
(Left) and after (Right) treatment with anti-HGF blocking antibodies. (Original
magnification: 3320.) (B) Met phosphorylation in MMP (lane 1), SV40-HMC
(lane 2), HMCySV40 (lane 3), and spBNL cells (lane 4) with (1) and without (2)
treatment with anti-HGF blocking antibodies. Equal amounts of proteins from
cell lysates were immunoblotted with antiphosphotyrosine antibodies.
GTL-16 cell line was used as a control of Met expression and phosphorylation.
Asterisks on the right indicate the positions of the pr170MET precursor (**) and
p145MET (*).
Fig. 8. Rb dependence of HGF autocrine circuit. (A) Solubilized proteins were
immunoprecipitated with Met antibodies and probed with the same Met
antibodies. Asterisks on the right of the blot indicate the positions of the
pr170MET precursor (**) and p145MET (*). The same filter was reprobed with
antiphosphotyrosine antibodies (B) and anti-Tag antibodies, using COS-7 as a
control of Tag expression (C). (D) RT-PCR and Southern hybridization specific
for HGF (nucleotides 646-1533). The MRC5 cell line was used as a control of
HGF expression.








































Rb family protein inactivation has been suggested (30). This
could be the mechanism that leads to HGF expression also in
mesothelial cells, as demonstrated by our results. Transfection of
HMC with Rb binding defective Tag mutants abolishes HGF
production and tyrosine phosphorylation of Met in ligand ab-
sence. The establishment of an autocrine circuit for growth
factors frequently confers a selective advantage to tumor cells as
well. In particular, the occurrence of an HGFyMet autocrine
loop has been reported in a number of cancers, including MM
(16). Moreover, in MDCK, the expression of recombinant Tag
has been reported to induce dissociation and motility (30). These
and our results suggest the existence of a Tag-dependent mech-
anism leading to Met phosphorylation in different cell lineages.
An issue that has been less clear is the constantly increased
Met receptor protein levels in HMC expressing the Tag protein.
This effect cannot be merely explained by the Met tyrosine
kinase activation, which has been demonstrated to enhance the
expression of the receptor itself (32), because Met expression is
elevated also in the presence of the Tag mutants failing to bind
Rb and to induce HGF. We postulate that some other mecha-
nisms, presently unknown, are involved in this Tag-dependent
transcriptional or posttranscriptional regulation. However, Met-
enhanced expression does not seem to be essential for the
observed biological effects because it is not associated to recep-
tor tyrosine phosphorylation, and treatments with suramin and
blocking antibodies reveal that Met activation and cell morphol-
ogy changes rely on HGF release.
The level of expression of Tag protein required to elicit the
biological effects observed in MM cells was quite low. This is in
accordance with other reports of human cell growth (8). A
possible explanation can be the simultaneous occurrence of
different lesions in other molecules involved in the cell-cycle
control (i.e., ARF proteins) (33). The low expression of ARF
proteins makes the cells more susceptible to DNA damage,
impairing their ability to repair any loss of genomic integrity.
On the whole, our study confirms that SV40, which is present in
the United States and in Europe in at least 60% of human
mesotheliomas (34, 35), plays a role of major importance in the
development of MM, cooperating with other causative agents.
Regarding the cancerogenic role of asbestos, the Tag-induced
HGF-dependent autocrine loop can additively sustain cell trans-
formation addressing HMC toward the neoplastic transformation.
The clinician should take in account of these findings when-
ever pleural plaques are detected in a patient because SV40 has
also been detected in hyperplastic HMC (36). The induction of
the HGF-dependent autocrine loop in these cells might render
the SV40-positive hyperplastic lesion at higher risk for malignant
transformation.
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